Verastem Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial
Reuters
Oct 24, 2025
<a href="https://laohu8.com/S/VSTM">Verastem</a> Reports Encouraging Early Results for KRAS G12D Inhibitor in Ongoing Phase 1/2a Trial
Verastem Inc. has announced encouraging preliminary data from its ongoing Phase 1/2a clinical trial evaluating VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in patients with previously-treated advanced KRAS G12D mutant solid tumors. The first two monotherapy dose levels (400 mg QD and 600 mg QD) have been cleared with no dose-limiting toxicities reported, and promising anti-tumor activity has been observed across various solid tumors, including advanced pancreatic ductal adenocarcinoma. Gastrointestinal tolerability has been favorable, with no nausea, vomiting, or diarrhea greater than Grade 1 observed. Patient enrollment has also begun for the first dose escalation combination cohort of VS-7375 with cetuximab in patients with advanced KRAS G12D mutant solid tumors, including colorectal cancer. Verastem plans to report an interim safety and efficacy update on the Phase 1/2a trial in the first half of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verastem Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251023370473) on October 23, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.